TACE/ADAM-17 and MMP inhibitor. Blocks shedding of TNF from cell membranes. Reduces pain-associated behavior in mice with a constructive mononeuropathy.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 10 mg/ml in DMSO and to 10 mg/ml in PBS|
Preparing Stock Solutions
The following data is based on the product molecular weight 499.6. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2 mL||10.01 mL||20.02 mL|
|5 mM||0.4 mL||2 mL||4 mL|
|10 mM||0.2 mL||1 mL||2 mL|
|50 mM||0.04 mL||0.2 mL||0.4 mL|
References are publications that support the products' biological activity.
Sommer et al (1997) A metalloprotease-inhibitor reduces pain associated behavior in mice with experimental neuropathy. Neurosci. Lett. 237 45 PMID: 9406876
Mohler et al (1994) Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 370 218 PMID: 8028669
If you know of a relevant reference for TAPI 1, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: TAPI 1, supplier, TAPI1, ADAM17, metalloproteases, MMPs, metalloproteinases, inhibits, inhibitors, adams, TNFa, TNFα, converting, enzyme, TACE, ADAMs, Matrix, Metalloprotease, ADAMs, Tocris Bioscience
Citations for TAPI 1
Citations are publications that use Tocris products.
Currently there are no citations for TAPI 1. Do you know of a great paper that uses TAPI 1 from Tocris? If so please let us know.
TAPI 1 Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.